Work

Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder

Year: 2020

Type: article

Abstract: The purpose of this study was to determine whether metformin promotes weight loss in overweight out-patients with chronic schizophrenia or schizoaffective disorder.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/2wg5-6a24

Authors: Golden, Lauren H., Catellier, Diane J., LaVange, Lisa, Ray, Neepa, Stewart, Dawn D., Hamer, Robert M., Jarskog, L. Fredrik, Lieberman, Jeffrey A., Stroup, T. Scott

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, CeNeRx, F. Hoffmann-La Roche, Sunovion, Mylan, H. Lundbeck A/S, Allergan

OpenAlex ID: W4298008659

FWCI:

Cites:

Cited by:

Related to: 10